MXPA05009660A - Derivados azabiciclicos de piridiloximetilo y bencisoxazol. - Google Patents

Derivados azabiciclicos de piridiloximetilo y bencisoxazol.

Info

Publication number
MXPA05009660A
MXPA05009660A MXPA05009660A MXPA05009660A MXPA05009660A MX PA05009660 A MXPA05009660 A MX PA05009660A MX PA05009660 A MXPA05009660 A MX PA05009660A MX PA05009660 A MXPA05009660 A MX PA05009660A MX PA05009660 A MXPA05009660 A MX PA05009660A
Authority
MX
Mexico
Prior art keywords
alkoxy
hydrogen
alkyl
pyridyloxymethyl
disorders
Prior art date
Application number
MXPA05009660A
Other languages
English (en)
Inventor
Bishop Wlodecki
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA05009660A publication Critical patent/MXPA05009660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto azabiciclico sustituido de aminometilpiridiloximetilo/bencisoxazol, una composicion farmaceutica que comprende el mismo y un metodo para tratar uno o mas trastornos del CNS u otros, que incluye el tratamiento concurrente de trastornos como esquizofrenia y depresion.
MXPA05009660A 2003-03-12 2004-02-23 Derivados azabiciclicos de piridiloximetilo y bencisoxazol. MXPA05009660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45392503P 2003-03-12 2003-03-12
PCT/IB2004/000499 WO2004081007A1 (en) 2003-03-12 2004-02-23 Pyridyloxymethyl and benzisoxazole azabicyclic derivatives

Publications (1)

Publication Number Publication Date
MXPA05009660A true MXPA05009660A (es) 2005-10-20

Family

ID=32990837

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009660A MXPA05009660A (es) 2003-03-12 2004-02-23 Derivados azabiciclicos de piridiloximetilo y bencisoxazol.

Country Status (31)

Country Link
US (1) US7345038B2 (es)
EP (1) EP1608648B1 (es)
JP (2) JP3910627B2 (es)
KR (2) KR100767854B1 (es)
CN (1) CN100389115C (es)
AP (1) AP2005003390A0 (es)
AR (1) AR043537A1 (es)
AU (2) AU2004220327B2 (es)
BR (1) BRPI0408248A (es)
CA (1) CA2518740C (es)
EA (1) EA009527B1 (es)
EC (1) ECSP056011A (es)
GT (1) GT200400041A (es)
HK (1) HK1085725A1 (es)
HR (1) HRP20050798A2 (es)
IL (1) IL170290A (es)
MA (1) MA27747A1 (es)
MX (1) MXPA05009660A (es)
NL (1) NL1025710C2 (es)
NO (1) NO20054095L (es)
OA (1) OA13038A (es)
PA (1) PA8597501A1 (es)
PE (1) PE20041057A1 (es)
PL (1) PL378749A1 (es)
RS (1) RS20050692A (es)
TN (1) TNSN05224A1 (es)
TW (1) TW200502234A (es)
UA (1) UA78437C2 (es)
UY (1) UY28225A1 (es)
WO (1) WO2004081007A1 (es)
ZA (1) ZA200506373B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994726B2 (en) * 2004-05-25 2006-02-07 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
ATE525377T1 (de) 2003-10-15 2011-10-15 Osi Pharm Inc Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
JP2007519705A (ja) * 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
AP2139A (en) 2004-04-02 2010-08-21 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
WO2006027692A2 (en) * 2004-09-10 2006-03-16 Pfizer Products Inc. Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
WO2009143051A1 (en) * 2008-05-19 2009-11-26 Osi Pharmaceuticals, Inc. Substituted imidazopyr-and imidazotri-azines
JP2012524119A (ja) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｃ−ピラジン−メチルアミンの調製
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2012052540A1 (en) * 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2016115282A1 (en) * 2015-01-13 2016-07-21 Vanderbilt University Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2023083445A1 (en) 2021-11-10 2023-05-19 Symrise Ag Compositions comprising trpm8 agonistic cooling agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
US5167034A (en) * 1990-06-18 1992-11-24 International Business Machines Corporation Data integrity for compaction devices
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
PL170889B1 (pl) 1991-09-25 1997-02-28 Pfizer S posób wytwarzania nowej (7S,9aS)-2-(benzo[d]izoksazoliio-3) perhydro-7-{2-[(2aS)-2a- hydroksy-3,3- czterometylenogluta-rimido]etyio}-1H-pirydo[1,2-a] pirazyny i nowej(7S,9aS)-2-(benzo[d]izoksazolilo-3) perhydro-7-{2[(2aR)-2a-hydroksy-3,3- czterometylenoglutarimido]-etylo}-1 H-pirydo[1,2-a] pirazyny PL PL
DE69326767T2 (de) 1992-06-16 2000-03-02 Pfizer Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica
US5731307A (en) 1994-09-30 1998-03-24 Pfizer, Inc. Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
EP0984965B1 (en) 1997-05-30 2004-05-19 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
PA8469101A1 (es) 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
DK1114028T3 (da) 1998-08-26 2007-04-30 Aventis Pharma Ltd Azabicykliske forbindelser, der modulerer inhibering af celleadhæsion
BR9913888A (pt) 1998-09-18 2002-01-08 Basf Ag Composto, e, métodos de inibir a atividade da proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
NZ510588A (en) 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
SG142120A1 (en) 1999-03-12 2008-05-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders

Also Published As

Publication number Publication date
NO20054095D0 (no) 2005-09-02
IL170290A (en) 2011-02-28
EA009527B1 (ru) 2008-02-28
TNSN05224A1 (fr) 2007-06-11
BRPI0408248A (pt) 2006-03-01
HK1085725A1 (en) 2006-09-01
CA2518740C (en) 2011-01-11
EP1608648B1 (en) 2012-07-18
CN100389115C (zh) 2008-05-21
JP2007051155A (ja) 2007-03-01
AU2010203303A1 (en) 2010-08-12
CA2518740A1 (en) 2004-09-23
KR100767854B1 (ko) 2007-10-17
NO20054095L (no) 2005-09-26
UA78437C2 (en) 2007-03-15
US7345038B2 (en) 2008-03-18
NL1025710C2 (nl) 2005-10-10
OA13038A (en) 2006-11-10
US20050026922A1 (en) 2005-02-03
AU2004220327B2 (en) 2010-06-24
JP3910627B2 (ja) 2007-04-25
PE20041057A1 (es) 2005-01-22
AR043537A1 (es) 2005-08-03
ZA200506373B (en) 2006-10-25
KR20050113221A (ko) 2005-12-01
RS20050692A (en) 2007-11-15
UY28225A1 (es) 2004-11-08
EA200501148A1 (ru) 2006-04-28
HRP20050798A2 (en) 2006-02-28
KR20070074667A (ko) 2007-07-12
PL378749A1 (pl) 2006-05-15
ECSP056011A (es) 2006-01-27
AP2005003390A0 (en) 2005-09-30
JP2006519830A (ja) 2006-08-31
TW200502234A (en) 2005-01-16
CN1759116A (zh) 2006-04-12
AU2004220327A1 (en) 2004-09-23
GT200400041A (es) 2005-03-23
PA8597501A1 (es) 2005-05-24
MA27747A1 (fr) 2006-02-01
WO2004081007A1 (en) 2004-09-23
NL1025710A1 (nl) 2004-09-14
EP1608648A1 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
MXPA05009660A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol.
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
AR040870A1 (es) Compuestos inhibidores de proteinquinasas y composicion farmaceutica que los comprende
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
TW200633979A (en) Method
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
TW200716528A (en) Cyclopropanecarboxamide derivatives
UY27503A1 (es) Nuevos derivados de piperazina
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
EA200600892A1 (ru) Новые хинолиновые производные
ATE524443T1 (de) Bicyclische inhibitoren von mek und verfahren zu deren herstellung
TW200505920A (en) Organic compounds
TW200612920A (en) Novel imidazolidine derivatives
MXPA05007494A (es) Nuevos compuestos.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
ATE398627T1 (de) C-2-modifizierte erythromycinderivate
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PT1210320E (pt) Aminobenzofenonas como inibidores de il-1beta e tnf-alfa
PT1202959E (pt) Aminobenzofenonas como inibidores de il-1-beta e tnf-alfa

Legal Events

Date Code Title Description
FG Grant or registration